Effectiveness and side effects of anti-CD20 therapy for autoantibody-mediated blistering skin diseases: A comprehensive survey of 71 consecutive patients from the Initial use to 2007

Therapeutics and Clinical Risk Management

Volumn 5, Issue 1, 2009, Pages 1-7

  Peterson, Jennifer D ^a   Chan, Lawrence S ^b,c  

^a TEXAS TECH UNIVERSITY HEALTH SCIENCES CENTER   (United States)

^b UNIVERSITY OF ILLINOIS AT CHICAGO   (United States)

^c JESSE BROWN VA MEDICAL CENTER   (United States)

Author keywords

Anti CD20; Blistering diseases; Epidermolysis bullosa acquisita; Pemphigus; Skin

Indexed keywords

AZATHIOPRINE; CD20 ANTIBODY; COLCHICINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DOXORUBICIN; IMMUNOGLOBULIN; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; RITUXIMAB; STEROID; VINCRISTINE;

ACUTE KIDNEY FAILURE; ADULT RESPIRATORY DISTRESS SYNDROME; ANEMIA; ARTICLE; BACTEREMIA; BLISTER; BRONCHOSPASM; BULLOUS DERMATITIS; BULLOUS PEMPHIGOID; CHICKENPOX; CHILL; CONGESTIVE HEART FAILURE; CYTOMEGALOVIRUS INFECTION; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DYSPNEA; EPIDERMOLYSIS BULLOSA ACQUISITA; FEVER; GRAFT VERSUS HOST REACTION; HEADACHE; HEART ARRHYTHMIA; HEART INFARCTION; HEPATITIS; HEPATITIS B; HERPES ZOSTER; HUMAN; INFECTIOUS ARTHRITIS; LEUKOPENIA; LICHENOID ERUPTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MEDLINE; MENINGOENCEPHALITIS; NAUSEA; NEUTROPENIA; ORTHOSTATIC HYPOTENSION; PARANEOPLASTIC PEMPHIGUS; PEMPHIGUS FOLIACEUS; PEMPHIGUS VEGETANS; PEMPHIGUS VULGARIS; PNEUMONIA; PROGRESSIVE MULTIFOCAL LEUKOENCEPHALOPATHY; PRURITUS; SEPSIS; SERUM SICKNESS; STEVENS JOHNSON SYNDROME; THROMBOCYTOPENIA; TOXIC EPIDERMAL NECROLYSIS; TUMOR LYSIS SYNDROME; URTICARIA; VASCULITIS;

EID: 72249116337     PISSN: 11766336     EISSN: 1178203X     Source Type: Journal    
DOI: None     Document Type: Article

References (45)

1. Arin MJ, Hunzelmann N. Anti-B-cell-directed immunotherapy (rituximab) in the treatment of refractory pemphigus - an update. Eur J Dermatol. 2005;15:224-30.
2. Kazkaz H, Isenberg D. Anti B cell therapy (rituximab) in the treatment of autoimmune diseases. Curr Opin Pharmacol. 2004;4:398-402.
3. Sundharam J. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Indian J Dermatol Venereol Leprol. 2006;72:173-4.
4. Virgolini L, Marzocchi V. Rituximab in autoimmune diseases. Biomed Pharmacother. 2004;58:299-309.
5. Arin MJ, Engert A, Krieg T, et al. Anti-CD20 monoclonal antibody (rituximab) in the treatment of pemphigus. Br J Dermatol. 2005;153:620-5.
6. Cooper HL, Healy E, Theaker JM, et al. Treatment of resistant pemphigus vulgaris with an anti-CD20 monoclonal antibody (rituximab). Clin Exp Dermatol. 2003;28:366-8.
7. Neidermeier A, Worl P, Barth S, et al. Delayed response of oral vulgaris to rituximab treatment. Eur J Dermatol. 2006;16:266-70.
8. Goebeler M, Herzog S, Brocker E-B, et al. Rapid response of treatment-resistant pemphigus foliaceus to the anti-CD20 antibody rituximab. Br J Dermatol. 2003;149:899-901.
9. Herrmann G, Engert A, Hunzelmann N. Treatment of pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Br J Dermatol. 2003;18:620-5.
10. Antonucci A, Negosanti M, Tabanelli M, et al. Treatment of refractory pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab): fi ve cases. J Dermatolog Treat. 2007;18:178-83.
11. Connelly EA, Aber C, Kleiner G, et al. Generalized erythrodermic pemphigus foliaceus in a child and its successful response to rituximab treatment. Pediatr Dermatol. 2007;24:172-6.
12. Marzano AV, Fanoni D, Venegoni L, et al. Treatment of refractory pemphigus with the anti-CD20 monoclonal antibody (rituximab). Dermatology. 2007;214:310-18.
13. Niedermeier A, Eming R, Pfütze M, et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol. 2007;143:192-8.
14. Ahmed AR, Spigelman Z, Cavacini LA, et al. Treatment of pemphigus vulgaris with rituximab and intravenous immune globulin. N Engl J Med. 2006;355:1772-9.
15. Schmidt E, Herzog S, Brocker E-B, et al. Long-standing remission of recalcitrant juvenile pemphigus vulgaris after adjuvant therapy with rituximab. Br J Dermatol. 2005;153:449-51.
16. Sami N, Bhol KC, Ahmed RA. Infl uence of intravenous immunoglobulin therapy on autoantibody titers to desmoglein 3 and desmoglein 1 in pemphigus vulgaris. Eur J Dermatol. 2003;13:377-81.
17. Cianchini G, Corona R, Frezzolini A, et al. Treatment of severe pemphigus with rituximab: report of twelve cases and a review of the literature. Arch Dermatol. 2007;143:1033-8.
18. Salopek TG, Logsetty S, Tredget EE. Anti-CD20 monoclonal antibody (rituximab) for the treatment of recalcitrant, life-threatening pemphigus vulgaris with implications in the pathogenesis of the disorder. J Am Acad Dermatol. 2002;47:785-8.
19. Virgolini L, Marzocchi V. Anti-CD20 monoclonal antibody (rituximab) in the treatment of autoimmune diseases. Successful result in refractory pemphigus vulgaris: report of a case. Haematologica. 2003;88:ELT24.
20. Belgi AS, Azeez M, Hoyle C, et al. Response of pemphigus vulgaris to anti-CD20 antibody therapy (rituximab) may be delayed. Clin Exp Dermatol. 2005;31:143.
21. Dupuy A, Viguier M, Bedane C, et al. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody). Arch Dermatol. 2004;140:91-6.
22. Espana A, Fernandez-Galar M, Lloret P, et al. Long-term complete remission of severe pemphigus vulgaris with monoclonal anti-CD20 antibody therapy and immunophenotype correlations. J Am Acad Dermatol. 2004;50:974-6.
23. Wenzel J, Bauer R, Bieber T, et al. Successful rituximab treatment of pemphigus vulgaris resistant to multiple immunosuppressants. Acta Derm Venereol. 2005;85:185-6.
24. Cechhi R, Gasperini U. Severe pemphigus vulgaris treated with rituximab (mabthera). J Dermatol. 2005;32:862-4.
25. Kong HK, Prose NS, Ware RE, et al. Successful treatment of refractory childhood pemphigus vulgaris with anti-CD20 monoclonal antibody (rituximab). Pediatr Dermatol. 2005;22:461-4.
26. Morrison LH. Therapy of refractory pemphigus vulgaris with monoclonal anti-CD20 antibody (rituximab). J Am Acad Dermatol. 2004;51:817-9.
27. Esposito M, Capriotti E, Gunta A, et al. Long-lasting remission of pemphigus vulgaris treated with rituximab. Acta Derm Venereol, 2006;86:87-9.
28. Johnston S, Kennedy C. Images in clinical medicine. Pemphigus foliaceus. N Engl J Med. 2005;353:2589.
29. Barnadas MA, Roe E, Brunet S, et al. Therapy of paraneoplastic pemphigus with rituximab: a case report and review of literature. J Eur Acad Dermatol Venereol. 2006;20:69-74.
30. Schadlow MB, Anhalt GJ, Sinha AA. Using rituximab (anti-CD20 antibody) in a patient with paraneoplastic pemphigus. J Drugs Dermatol. 2003;2:564-7.
31. Van Rossum MM, Verhaegan NTM, Jonkman MF, et al. Follicular non-Hogkin's lymphoma with refractory paraneoplastic pemphigus: case report with review of novel treatment modalities. Leuk Lymphoma. 2004;45:2327-32.
32. Borradori L, Lombardi T, Samson J, et al. Anti-CD20 monoclonal antibody (rituximab) for refractory erosive stomatitis secondary to CD20+ follicular lymphoma-associated paraneoplastic pemphigus. Arch Dermatol. 2001;137:269-72.
33. Hoque SR, Black MM, Cliff S. Paraneoplastic pemphigus associated with CD20-positive follicular non-Hodgkin's lymphoma treated with rituximab: a third case resistant to rituximab therapy. Clin Exp Dermatol. 2007;32:172-5.
34. Szabolcs P, Reese M, Yancey KB, et al. Combination treatment of bullous pemphigoid with anti-CD20 and anti-CD25 antibodies in a patient with chronic graft-versus-host disease. Bone Marrow Transplant. 2002;30:327-9.
35. Schmidt E, Benoit S, Brocker E-B, et al. Successful adjuvant treatment of recalcitrant epidermolysis bullosa acquisita with anti-CD20 antibody rituximab. Arch Dermatol. 2006;142:147-50.
36. Crichlow SM, Mortimer NH, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titer epidermolysis bullosa acquisita. Br J Dermatol. 2007;156:194-6.
37. Scheinfeld N. A review of rituximab in cutaneous medicine. Dermatol Online J. 2006;12:3.
38. Sambrook PN. How to prevent steroid induced osteoporosis. Ann Rheum Dis. 2005;64:176-8.
39. Frediani B, Falsetti P, Baldi F, et al. Effects of 4-year treatment with once-weekly clodronate on prevention of corticosteroid-induced bone loss and fractures in patients with arthritis: evaluation with dual-energy x-ray absorptiometry and quantitative ultrasound. Bone. 2003;33:575-81.
40. Cranney A, Adachi JD. Corticosteroid-induced osteoporosis: a guide to optimum management. Treat Endocrinol. 2002;1:271-9.
41. Schmidt E, Hunzelmann N, Zillikens D, et al. Rituximab in refractory autoimmune bullous diseases. Clin Exp Dermatol. 2006;31:503-8.
42. El Tal AK, Posner MR, Spigelman Z, et al. Rituximab: a monoclonal antibody to CD20 used in the treatment of pemphigus vulgaris. J Am Acad Dermatol. 2006;55:449-59.
43. Corneley OA, Heidecke CN, Karthaus M. Opportunistic infections (OI) following monoclonal antibody treatment. 2005 ASCO Annual Meeting. J Clin Oncol. 2005;23(16 Suppl):2562.
44. Schutgens RE. Rituximab-induced serum sickness. Br J Haematol. 2006;135:147.
45. Rituxan. Rituxan (rituximab) package insert. Cited 2007 May 28. Available from http://www.rituxan.com/.